Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A

1st Edition, Volume 365 - October 21, 2021
Editors: Niccolo Bartalucci, Lorenzo Galluzzi
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 8 9 9 3 9 - 0
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 8 9 9 4 0 - 6

Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A, Volume 365 in the International Review of Cell and Molecular Biology series reviews and details current… Read more

Purchase options

ROBOTICS & AUTOMATION

Empowering Progress

Up to 25% off Essentials Robotics and Automation titles

Explore now

Image with Robotics & Automation book covers

Institutional subscription on ScienceDirect

Request a sales quote

Cellular and Molecular Aspects of Myeloproliferative Neoplasms - Part A, Volume 365 in the International Review of Cell and Molecular Biology series reviews and details current advances in cell and molecular biology. Chapters in this new release include MPN a continuum of different disease entities, Bone marrow microenvironment of MPN, Extramedullary hemopoiesis in MPN, The JAK2 mutation, Calreticulin mutations in myeloproliferative neoplasms, and Cytogenetic abnormalities and non-driver mutations in MPN. The IRCMB series has a worldwide readership, maintaining a high standard by publishing invited articles on important and timely topics that are authored by prominent cell and molecular biologists.

The articles published in IRCMB have a high impact and an average cited half-life of 9 years. This great resource ranks high amongst scientific journals dealing with cell biology.

Cover image
Title page
Table of Contents
Copyright
Contributors
Philadelphia-negative myeloproliferative neoplasms: From origins to new perspectives
References
Chapter One: Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities
Abstract
2: Clinical characteristics of MPNs
3: Genetics of MPNs
4: Diagnostic criteria of MPNs
5: Clinical and molecular-integrated prognostic scores in MPNs
6: Current standard treatment in MPNs
7: Evolving therapies and clinical trials in MPNs
References
Acknowledgments
Chapter Two: Bone marrow microenvironment of MPN cells
Abstract
1: Introduction
2: The bone marrow niche in myeloproliferative neoplasms
3: The bone marrow extracellular matrix components in MPNs
4: Conclusions
References
Chapter Three: Extramedullary hematopoiesis in myeloproliferative neoplasms: Pathophysiology and treatment strategies
Abstract
1: Introduction
2: Extramedullary hematopoiesis
3: Pathophysiology of EMH
4: Therapeutic strategies
5: JAK inhibitors
6: Radiation and surgical intervention
7: Hematopoietic stem cell transplant (HSCT)
8: Non-JAK inhibitor pharmaceutical approaches
9: Emerging research
10: Conclusion
References
Chapter Four: The JAK2 mutation
Abstract
1: JAK2: A non-receptor tyrosine kinase
2: JAK2 mutations in Ph-myeloproliferative neoplasms
3: Aberrant signaling downstream of JAK2V617F
4: Factors determining phenotypes in JAK2V617F-positive MPNs
5: Cellular effects of JAK2V617F
6: Concluding remarks
References
Chapter Five: The MPL mutation
Abstract
1: Thrombopoietin receptor-MPL physiology
2: MPL mutations in myeloproliferative neoplasms
References
Chapter Six: Calreticulin mutations in myeloproliferative neoplasms
Abstract
1: Function of calreticulin
2: CALR mutations
3: Clinical features of CALR-mutant MPN
4: Molecular mechanism of MPL activation
5: CALR mutation and disruption of intracellular homeostasis
6: Effects on stem cells and cell differentiation
7: Disruption of the immune system
8: Treatment targeting mutant CALR protein
9: Remaining questions
10: Toward a breakthrough in MPN treatment
References

Niccolo Bartalucci

Niccolo Bartalucci practices in Florence, Italy. Dr. Bartalucci is highly rated in 6 conditions, according to our data. His top areas of expertise are Essential Thrombocythemia, Myelofibrosis, Polycythemia Vera, and Splenomegaly. His clinical research consists of co-authoring 34 peer reviewed articles in the past 15 years.

Affiliations and expertise

Department of Experimental and Clinical Medicine, University of Florence, Italy

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.

Affiliations and expertise

Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health